EPO Patent EP3722318A1: Multispecific Antigen-Binding Molecules

The European Patent Office has published patent application EP3722318A1 concerning multispecific antigen-binding molecules, filed by Regeneron Pharmaceuticals, Inc. The publication date is March 11, 2026, and it covers various classifications related to antibodies and their uses.

FGFR-Targeted Antagonistic Short Peptide Patent Application

The European Patent Office has published patent application EP2021115258A1 concerning an FGFR-targeted antagonistic short peptide. The application was published on March 11, 2026, with Wenzhou Medical University listed as the applicant.

EPO Patent Application EP3981790A1 - CD73 Binding Molecule

The European Patent Office has published patent application EP3981790A1 concerning a CD73 binding molecule and its use, filed by Jacobio Pharmaceuticals Co., Ltd. This publication provides notice of the patent application's details, including inventors and classifications.

EPO Patent Bulletin: Chimeric Antigen Receptor Cells Targeting ALK

The European Patent Office published patent application EP3978611A1 concerning chimeric antigen receptor-expressing cells targeting ALK. The patent application was filed by Shinshu University and lists multiple inventors. The publication date is March 11, 2026.

EPO Patent Publication EP4048683A2: Variant Alpha-Amylases

The European Patent Office has published patent application EP4048683A2 concerning variant maltopentaose/maltohexaose-forming alpha-amylases, with Danisco US Inc. listed as the applicant. This publication is part of the EPO's regular bulletin for the C07K classification, related to peptides.

Halogenated Antimicrobial Peptoids Patent EP3962925A1

The European Patent Office published patent application EP3962925A1 on March 11, 2026, concerning Halogenated Antimicrobial Peptoids. The patent application lists Maxwell Biosciences, Inc. as the applicant and details inventors Natalia Molchanova, Havard Jenssen, and Annelise Barron.

Anti-CD45 Antibody Drug Conjugates Patent Application EP3958910A1

The European Patent Office has published patent application EP3958910A1 concerning anti-CD45 antibody drug conjugates and their uses. The application was filed by Regeneron Pharmaceuticals, Inc. and lists multiple inventors. The publication date is March 11, 2026.

ABL Bio Inc. Anti-4-1BB Antibody Patent Publication

The European Patent Office has published patent application EP3887403A1 by ABL Bio Inc. for an anti-4-1BB antibody and its use. This publication relates to intellectual property protection for novel therapeutic agents.

Patent EP3893930A1: Monoclonal Antibodies Against Human Dickkopf3

The European Patent Office has published patent application EP3893930A1 concerning monoclonal antibodies against human Dickkopf3 and their uses. The patent was published on March 11, 2026, with the Board of Regents, The University of Texas System listed as the applicant.

EPO Patent Bulletin: WT1 Peptides for Preventing Polyposis

The European Patent Office has published patent application EP3865146A1 concerning WT1 peptides and analogs for preventing or treating familial adenomatous polyposis and non-hereditary colorectal adenoma. The application lists the International Institute of Cancer Immunology, Inc. as the applicant.